A cancer drug carries its approval like a promise, but a growing body of research suggests that promise was made to someone else. Scientists from Zurich, Yale, and Harvard have found that one in three cancer therapies approved in the United States—and one in five in Europe—are routinely administered to patients whose profiles were never included in the trials that justified those approvals. This is not a minor technical discrepancy; it is a quiet erosion of the evidentiary foundation upon which modern medicine rests, leaving patients and physicians navigating treatment decisions in the dark.
El País
· Sep 16, 2024
· health
· 5 min de lectura
High
Verificación: Verificado
Cancer drugs approved for patient profiles untested in clinical trials
Cancer patients receive medications without evidence of safety or efficacy in their specific disease profiles, risking serious adverse effects and treatment failure.
◉
Health & Medicine
2812 artículos relacionados
FDA approves Wegovy for heart disease prevention, expanding blockbuste…
infobae · 99% coincidencia
El ARN mensajero abre camino a vacunas contra 30 enfermedades infeccio…
infobae · 90% coincidencia
Weight-Loss Drugs Show Promise in Reducing Alcohol Cravings, But Clini…
infobae · 90% coincidencia
WHO endorses GLP-1 weight-loss drugs, issues first clinical guidance a…
El Tiempo · 90% coincidencia
Ozempic: Riesgos crecientes por uso estético sin supervisión médica
Medio digital El Zorro Nortino · 90% coincidencia
Cobertura Relacionada
El Mostrador · Aug 23
Guía de alimentos a limitar para proteger la salud cardiovascular
Expertos recomiendan limitar embutidos, bebidas azucaradas y ultraprocesados para reducir riesgos cardiovasculares. La a…
OkDiario · Aug 23 La boca seca no es una molestia menor: cuándo consultar al médicoLa xerostomía o boca seca es un problema infradiagnosticado que afecta a una de cada tres personas mayores de 60 años, f…
Segre.com · Aug 23 Programa pionero de ejercicio monitorizado mejora la salud cardiopulmonar en LleidaUn programa pionero en Lleida utiliza ejercicio físico monitorizado y análisis de 30 variables metabólicas para mejorar …
El País · Aug 23 No habrá una vacuna contra el cáncer, sino una distinta para cada paciente y tumorModerna y MSD avanzan hacia la aprobación de una vacuna de ARN mensajero personalizada contra el melanoma que reduce un …
Sesgo y Encuadre
⚖
El País presents research findings critically examining cancer drug approval practices, using dramatic medical framing to highlight safety concerns without apparent editorial bias toward specific stakeholders.
Bias Direction
center-left
Confidence
MED
Problem-focused investigative journalism that emphasizes systemic failures in drug approval processes and pharmaceutical pricing practices. Opens with dramatic medical metaphors ('batalla', 'contienda') to establish gravity, then pivots to critical examination of regulatory gaps and industry practices.
lucha contra el cáncer es una de las mayores batallas de la historia
contienda empieza en los laboratorios
expectativas no siempre se cumplen
elevada toxicidad
políticas de las farmacéuticas de imponer...precios que triplican
pone en riesgo la sostenibilidad
Pharmaceutical industry response or justification for approval practices
Regulatory agency (FDA/EMA) perspective on approval criteria and patient population decisions
Economic arguments regarding drug development costs and pricing
Perspective from patients who benefited from off-label or expanded use approvals
Counterarguments about innovation incentives and accelerated approval pathways
Impacto Geopolítico
🌎
Research reveals regulatory gaps in cancer drug approvals: 1 in 3 US and 1 in 5 European approvals used off-label for untested patient profiles, raising safety concerns and healthcare sustainability issues.
Escalation Risk
moderate
Confidence
HIGH
United States
European Union
Global healthcare systems
Shift in regulatory scrutiny toward pharmaceutical industry practices; academic institutions (Zurich, Yale, Harvard) gaining influence in drug safety discourse; potential tension between pharma pricing power and healthcare system sustainability across developed nations.
Similar to thalidomide crisis (1960s) where inadequate testing led to widespread harm, though current issue involves off-label use rather than initial approval fraud; reflects ongoing tension between accelerated drug approval and patient safety.
Lente Económico
📈
One-third of US and one-fifth of European cancer drugs are prescribed to untested patient profiles, raising safety concerns and threatening healthcare system sustainability amid high drug pricing.
Market Signal
bearish
Confidence
HIGH
Pharmaceutical manufacturing
Healthcare services
Medical devices and diagnostics
Health insurance
Hospital administration
Patients face increased health risks from off-label use of inadequately tested drugs; households bear rising out-of-pocket costs as cancer drug prices triple those of other treatments, straining family finances and healthcare budgets.
Regulatory bodies (FDA, EMA) may tighten approval processes requiring broader patient population testing; governments may implement price controls or reference pricing for oncology drugs; healthcare systems may restrict reimbursement to tested populations; potential litigation against pharmaceutical companies for off-label marketing.